Total Payments
$6,262
2024 Payments
$1,621
Companies
70
Transactions
355
Medicare Patients
1,595
Medicare Billing
$311,592
Payment Breakdown by Category
Food & Beverage$6,163 (98.4%)
Education$99.00 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,163 | 354 | 98.4% |
| Education | $99.00 | 1 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $574.66 | 50 | $0 (2024) |
| Amgen Inc. | $423.78 | 18 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $392.97 | 23 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $342.39 | 20 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $229.85 | 14 | $0 (2024) |
| Genentech USA, Inc. | $217.93 | 12 | $0 (2024) |
| Janssen Biotech, Inc. | $213.20 | 12 | $0 (2024) |
| Incyte Corporation | $202.87 | 10 | $0 (2024) |
| Astellas Pharma US Inc | $194.38 | 10 | $0 (2024) |
| PFIZER INC. | $175.55 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,621 | 95 | Celgene Corporation ($207.93) |
| 2023 | $1,427 | 79 | Celgene Corporation ($155.00) |
| 2022 | $1,358 | 81 | Celgene Corporation ($153.35) |
| 2021 | $748.24 | 43 | Amgen Inc. ($146.77) |
| 2020 | $383.81 | 23 | Amgen Inc. ($56.48) |
| 2019 | $244.97 | 10 | Kite Pharma, Inc. ($115.82) |
| 2018 | $390.75 | 19 | Amgen Inc. ($137.12) |
| 2017 | $88.12 | 5 | Eisai Inc. ($22.84) |
All Payment Transactions
355 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: Oncology | ||||||
| 12/16/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.94 | General |
| Category: Hematology | ||||||
| 12/10/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $16.84 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $18.72 | General |
| Category: Oncology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $21.71 | General |
| 11/25/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.19 | General |
| Category: Hematology | ||||||
| 11/21/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $1.05 | General |
| Category: Hematology | ||||||
| 11/18/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $19.15 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $17.72 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: Oncology | ||||||
| 11/04/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $5.43 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.51 | General |
| Category: Hematology | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $17.14 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $21.48 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: BioOncology | ||||||
| 09/24/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.79 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 577 | 1,040 | $217,820 | $112,070 |
| 2022 | 7 | 465 | 872 | $186,886 | $97,166 |
| 2021 | 8 | 390 | 678 | $145,189 | $74,746 |
| 2020 | 6 | 163 | 255 | $62,034 | $27,610 |
Total Patients
1,595
Total Services
2,845
Medicare Billing
$311,592
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 123 | 305 | $67,405 | $38,858 | 57.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 142 | 280 | $46,200 | $25,470 | 55.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 29 | 92 | $17,848 | $10,192 | 57.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 65 | 72 | $25,488 | $9,743 | 38.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 45 | 45 | $18,000 | $7,272 | 40.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 37 | 63 | $11,466 | $5,688 | 49.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 39 | 72 | $9,864 | $5,127 | 52.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 44 | $5,588 | $2,742 | 49.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 17 | 17 | $4,726 | $2,277 | 48.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $5,985 | $2,162 | 36.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 14 | $3,346 | $1,420 | 42.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 17 | $1,904 | $1,120 | 58.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 95 | 262 | $57,902 | $34,627 | 59.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 85 | 193 | $31,845 | $16,934 | 53.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 71 | 73 | $25,842 | $11,417 | 44.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 33 | 99 | $19,206 | $11,048 | 57.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 41 | 41 | $16,400 | $6,893 | 42.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 47 | 67 | $12,194 | $5,418 | 44.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 24 | 52 | $7,124 | $3,638 | 51.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 22 | 22 | $6,116 | $3,002 | 49.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 35 | 51 | $6,477 | $2,868 | 44.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $3,780 | $1,321 | 35.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 48 | 153 | $33,813 | $20,999 | 62.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 67 | 74 | $26,196 | $11,796 | 45.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 55 | 99 | $16,307 | $9,783 | 60.0% |
About Dr. David Macari, M.D
Dr. David Macari, M.D is a Hospitalist healthcare provider based in Sylvania, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/09/2014. The National Provider Identifier (NPI) number assigned to this provider is 1992116123.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Macari, M.D has received a total of $6,262 in payments from pharmaceutical and medical device companies, with $1,621 received in 2024. These payments were reported across 355 transactions from 70 companies. The most common payment nature is "Food and Beverage" ($6,163).
As a Medicare-enrolled provider, Macari has provided services to 1,595 Medicare beneficiaries, totaling 2,845 services with total Medicare billing of $311,592. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospitalist
- Other Specialties Hospitalist, Student in an Organized Health Care Education/Training Program
- Location Sylvania, OH
- Active Since 05/09/2014
- Last Updated 11/03/2023
- Taxonomy Code 208M00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1992116123
Products in Payments
- REBLOZYL (Biological) $331.05
- COSELA (Drug) $145.74
- JAKAFI (Drug) $141.69
- Pomalyst (Drug) $137.77
- BRUKINSA (Drug) $137.20
- clonoSEQ (Device) $132.60
- TIBSOVO (Drug) $127.67
- Lenvima (Drug) $122.79
- Yescarta (Drug) $115.82
- ENHERTU (Biological) $108.97
- IMBRUVICA (Drug) $107.23
- Enhertu (Drug) $100.65
- AYVAKIT (Drug) $99.04
- ZEPZELCA (Drug) $98.93
- PADCEV (Biological) $95.76
- LIBTAYO (Biological) $92.80
- OPDUALAG (Drug) $92.38
- Xtandi (Drug) $90.75
- GILOTRIF (Drug) $89.49
- LYNPARZA (Drug) $85.87
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.